Vascular endothelial growth factor in colorectal cancer |
| |
| Authors: | Guba Markus Seeliger Hendrik Kleespies Axel Jauch Karl-Walter Bruns Christiane |
| |
| Affiliation: | (1) Department of Surgery, University Clinic Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany |
| |
| Abstract: | ![]()
Background Angiogenesis plays an important role in colorectal cancer progression. Evidence from preclinical and clinical studies indicates that vascular endothelial growth factor (VEGF) is the predominant angiogenic factor in human colorectal cancer and is associated with formation of metastases and poor prognosis. Based on these results it was hypothesized that attacking one or more of the VEGF-mediated mechanisms may be promising in the treatment of colorectal cancer.Aims This article reviews the role of VEGF in colon cancer and summarizes recent advances in the treatment of colorectal cancer by anti-VEGF strategies.M. Guba and H. Seeliger contributed equally to this paper |
| |
| Keywords: | Anti-angiogenic therapy Clinical trials targeting VEGF Colorectal cancer Colorectal cancer metastases Prognostic value VEGF VEGF pathway |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
